Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_assertion type Assertion NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_head.
- NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_assertion description "[Here we have studied first-degree relatives of patients with type 2 diabetes to investigate whether a reduction in components of the insulin signal transduction pathways, such as the insulin receptor (InsR) or InsR substrate 1 or 2 (IRS1 or IRS2), or a reduction in genetic modifiers of insulin action, such as the TIMP3/ADAM17 (tissue inhibitor of metalloproteinase 3/A disintegrin and metalloprotease domain 17) pathway, is associated with evidence of atherosclerosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_provenance.
- NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_assertion evidence source_evidence_literature NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_provenance.
- NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_assertion SIO_000772 21984580 NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_provenance.
- NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_assertion wasDerivedFrom befree-20150227 NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_provenance.
- NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_assertion wasGeneratedBy ECO_0000203 NP515351.RAmtIfybb1Y6PYcixAAGq3sSbzI0lySZpFOG4c3qvC7Dc130_provenance.